Merck to initiate new clinical programme with lower dose of daily oral Islatravir in combination… EP News Bureau Sep 21, 2022 Phase-II study evaluating an investigational weekly oral combination treatment regimen of Islatravir and Gilead Sciences’…
Gilead and Merck initiate phase-II study on Lenacapavir and Islatravir oral combo for HIV-1… EP News Bureau Oct 27, 2021 This clinical study is the first from Merck and Gilead’s collaboration to develop potential long-acting HIV treatment options
Gilead, Merck sign pact to develop, commercialise long-acting HIV treatment combinations EP News Bureau Mar 15, 2021 Collaboration to focus on oral and injectable formulations of Lenacapavir and Islatravir
